Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LeuTech Studies In Neutropenic Patients Suggested By FDA Committee

Executive Summary

Palatin and co-development partner Mallinckrodt should conduct studies with LeuTech to verify efficacy in neutropenic patients and to ensure that the radiolabeled monoclonal antibody imaging agent does not damage white blood cells, FDA's Medical Imaging Drugs Advisory Committee suggested during a July 10 meeting.

You may also be interested in...

Palatin LeuTech Diagnostic Cost-Effectiveness Analysis Under Way

Palatin Technologies is conducting a cost-effectiveness analysis to support use of LeuTech to aid in the diagnosis of equivocal appendicitis.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts